Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

FDA green light for diagnostic Phase 1 pancreatic trial

Tuesday, October 17, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has received FDA approval to initiate a Phase 1 clinical trial for a diagnostic targeting pancreatic conditions. This trial represents a significant step forward in the company's efforts to develop innovative diagnostic tools. The approval is expected to enhance the understanding and treatment of pancreatic diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA approval marks a significant milestone for Radiopharm Theranostics.
  • Initiation of Phase 1 trial could lead to advancements in pancreatic diagnostics.
  • Potential to improve patient outcomes with new diagnostic methods.

Full Press Release Details

• Announcements
• Price Sensitive
• October 17, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• October 26, 2022
• Announcements
• December 6, 2022
• Announcements
• June 13, 2023
• Announcements
• June 4, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What trial did Radiopharm Theranostics receive FDA approval for?

Radiopharm Theranostics received FDA approval to initiate a Phase 1 clinical trial.

What is the focus of the Phase 1 trial?

The Phase 1 trial focuses on developing a diagnostic for pancreatic conditions.

Why is this FDA approval significant?

This approval is a major milestone for Radiopharm Theranostics in advancing pancreatic diagnostics.

What could this trial lead to?

The trial could lead to improved diagnostic methods and better patient outcomes.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics FDA approval pancreatic diagnostics clinical trial Phase 1
Last updated: Oct 17, 2023